跳至主要内容
临床试验/NCT04972682
NCT04972682已完成不适用

Tailoring Postoperative Management Through Sentinel Lymph Node Biopsy in Low- and Intermediate-Risk Endometrial Cancer: a Prospective Open-label Single-arm Clinical Trial

Moscow City Oncology Hospital No. 622 个研究点 分布在 2 个国家目标入组 102 人开始时间: 2021年7月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
102
试验地点
2
主要终点
Change in postoperative treatment strategy

研究概览

简要总结

While total hysterectomy without lymph node staging is standard for low- and intermediate-risk endometrial cancer, certain histopathologic factors can necessitate additional interventions. Our study assesses the influence of sentinel lymph node (SLN) biopsy on postoperative decision-making.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Age ≥18 years
  • Histologically verified low-grade endometrioid adenocarcinoma of the endometrium (G1-G2)
  • FIGO stage IA
  • FIGO stage IB and II when LND is contraindicated
  • No contraindications for surgery
  • Signed informed consent

排除标准

  • • Age <18 years
  • Presence of tumor spread outside the corpus uteri
  • Absence of tumor invasion into the myometrium
  • High-grade tumor (G3)
  • Bokhman type 2 tumor (e.g., clear cell adenocarcinoma, serous adenocarcinoma, carcinosarcoma, endometrial stromal sarcoma)
  • Preoperative treatment of endometrial cancer including radiotherapy, systemic chemotherapy, or hormone therapy
  • Prior pelvic or retroperitoneal LND
  • History of surgeries on the uterus and uterine appendages, with exceptions such as cesarean section, tubectomy, oophorectomy, ovarian resection, ovarian biopsy, and ovarian cauterization
  • Allergy to iodine-containing drugs
  • Contraindications to surgical treatment
  • Lack of signed informed consent

结局指标

主要结局

Change in postoperative treatment strategy

时间窗: Up to 3 weeks after surgery

The rate of change in postoperative treatment based on the SLNB results and postoperative histology (percentage). A change in postoperative treatment strategy is defined as any difference between treatment plans set by the tumor board before and after receiving the SLN biopsy information.

次要结局

  • Adjustments in FIGO staging(Up to 3 weeks after surgery)
  • Major postoperative morbidity(Up to 30 days after surgery)
  • Bilateral SLN detection(At the end of the surgery - 1 day)
  • The rate of intraoperative complications of SLN biopsy(At the end of the surgery - 1 day)
  • Details of intraoperative complications of SLN biopsy(At the end of the surgery - 1 day)
  • Time to pelvic recurrence(24 months after surgery)
  • Postoperative mortality(Up to 30 days after surgery)
  • Incidence of lymphedema(Up to 24 months after surgery)
  • Pelvic recurrence rate(24 months after surgery)

研究者

发起方
Moscow City Oncology Hospital No. 62
申办方类型
Other Gov
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

[SENTRY] Tailoring Postoperative Management Through... | 临床试验